IL218948A0 - Use of rasagiline for the treatment of progressive supranuclear palsy - Google Patents

Use of rasagiline for the treatment of progressive supranuclear palsy

Info

Publication number
IL218948A0
IL218948A0 IL218948A IL21894812A IL218948A0 IL 218948 A0 IL218948 A0 IL 218948A0 IL 218948 A IL218948 A IL 218948A IL 21894812 A IL21894812 A IL 21894812A IL 218948 A0 IL218948 A0 IL 218948A0
Authority
IL
Israel
Prior art keywords
rasagiline
treatment
progressive supranuclear
supranuclear palsy
palsy
Prior art date
Application number
IL218948A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL218948A0 publication Critical patent/IL218948A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL218948A 2009-10-09 2012-03-29 Use of rasagiline for the treatment of progressive supranuclear palsy IL218948A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27867709P 2009-10-09 2009-10-09
PCT/IB2010/002852 WO2011042812A1 (en) 2009-10-09 2010-10-08 Use of rasagiline for the treatment of progressive supranuclear palsy

Publications (1)

Publication Number Publication Date
IL218948A0 true IL218948A0 (en) 2012-07-31

Family

ID=43533485

Family Applications (1)

Application Number Title Priority Date Filing Date
IL218948A IL218948A0 (en) 2009-10-09 2012-03-29 Use of rasagiline for the treatment of progressive supranuclear palsy

Country Status (7)

Country Link
US (1) US20110130466A1 (enExample)
EP (1) EP2485722A1 (enExample)
JP (1) JP2013507352A (enExample)
AU (1) AU2010304755A1 (enExample)
CA (1) CA2777185A1 (enExample)
IL (1) IL218948A0 (enExample)
WO (1) WO2011042812A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
WO2009154777A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
EP2939669A1 (en) * 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-keto-n-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098685A (zh) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 雷沙吉兰经口崩解组合物
MX2008012479A (es) * 2006-03-29 2009-08-13 Velacor Therapeutics Pty Ltd Tratamiento de enfermedades neurodegenerativas.
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
WO2009154777A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
CA2727021A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
AU2011282716A1 (en) * 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) * 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EA201390613A1 (ru) * 2010-10-26 2013-11-29 Тева Фармасьютикал Индастриз Лтд. Обогащенный дейтерием расагилин
KR20140090996A (ko) * 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
AU2012323351A1 (en) * 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan

Also Published As

Publication number Publication date
EP2485722A1 (en) 2012-08-15
WO2011042812A1 (en) 2011-04-14
AU2010304755A1 (en) 2012-05-24
JP2013507352A (ja) 2013-03-04
US20110130466A1 (en) 2011-06-02
CA2777185A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
IL218948A0 (en) Use of rasagiline for the treatment of progressive supranuclear palsy
ZA201209725B (en) Composition for improving sexual wellness
GB0921731D0 (en) Theraputic uses
ZA201202504B (en) Process for the preparation of calcobutrol
SI2362764T1 (sl) Naprava za mobiliziranje telesa
AU329518S (en) Massage apparatus
EP2436359A4 (en) GODEMICHÉ FOR SEXUAL STIMULATION
GB2482817B (en) Novel use
PL390042A1 (pl) Sposób wytwarzania kwasu chlebowego
EP2440216A4 (en) USE OF A COMPOSITION FOR TREATING MUCOSITIS
PL388931A1 (pl) Sposób otrzymywania fluorokarbofunkcyjnych silseskwioksanów
ZA201107111B (en) Process for the preparation of layered silicates
GB0905189D0 (en) Improvements relating to crutches
GB0905864D0 (en) Novel use
GB0916744D0 (en) Crutch aid
SI2430078T1 (sl) Postopek za pripravo sevelamerja
PT2536398T (pt) Tratamento da osteoporose
TWM365740U (en) Massager structure
PL389594A1 (pl) Sposób wytwarzania sulfidów fluorohalogenometyloarylowych
TWM365741U (en) Tepid massager
TWI365054B (en) Crutch structure
TWM372715U (en) Sound-controlled massager
HU0900505D0 (en) Sexual stimulation devices
TWM365745U (en) Adjustable crutch
GB0918382D0 (en) Osteoporosis treatment